Predictive and Prognostic Factors of Synchronous Colorectal Lung-Limited Metastasis

Table 1

The characteristics of CRC patients associated with lung-limited metastasis.

Characteristics	Total ()		Without lung-limited metastasis ()		With lung-limited metastasis ()		value
		%		%		%
Gender							0.899
Female	80313	47.44%	79695	47.44%	618	47.61%
Male	88992	52.56%	88312	52.56%	680	52.39%
Age (years)							0.072
<65	70997	41.93%	70425	41.92%	572	44.07%
65-74	44114	26.06%	43776	26.06%	338	26.04%
≥75	54194	32.01%	53806	32.03%	388	29.89%
Marital status							0.001
Married	89491	52.86%	88863	52.89%	628	48.38%
Unmarried/NOS	79814	47.14%	79144	47.11%	670	51.62%
Insurance							0.141
Yes	160889	95.03%	159667	95.04%	1222	94.14%
No/unknown	8416	4.97%	8340	4.96%	76	5.86%
Race							0.010
White	133791	79.02%	132814	79.05%	977	75.27%
Black	18894	11.16%	18711	11.14%	183	14.10%
Other/NOS	16620	9.82%	16482	9.81%	138	10.63%
Tumor location							<0.001
Right colon	72060	42.56%	71738	42.70%	322	24.81%
Left colon	45969	27.15%	45677	27.19%	292	22.50%
Rectum	49013	28.95%	48345	28.78%	668	51.46%
NOS	2263	1.34%	2247	1.34%	16	1.23%
Pathological grade							<0.001
I/II	130151	76.87%	129242	76.93%	909	70.03%
III/IV	25628	15.14%	25427	15.13%	201	15.49%
Unknown	13526	7.99%	13338	7.94%	188	14.48%
Histological type							0.016
Adenocarcinomas	156108	92.21%	154888	92.19%	1220	93.99%
MCC/SRCC	13197	7.79%	13119	7.81%	78	6.01%
T stage							<0.001
Tis-2	65332	38.59%	65117	38.76%	215	16.56%
T3	83185	49.13%	82444	49.07%	741	57.09%
T4	20788	12.28%	20446	12.17%	342	26.35%
N stage							<0.001
N0	110089	65.02%	109619	65.25%	470	36.21%
N1	40665	24.02%	40144	23.89%	521	40.14%
N2	18551	10.96%	18244	10.86%	307	23.65%
Colectomy/proctectomy							<0.001
Standard resection	121185	71.58%	120545	71.75%	640	49.31%
Simplified resection	26208	15.48%	26017	15.49%	191	14.71%
Nonresection/NOS	21912	12.94%	21445	12.76%	467	35.98%
Pulmonary surgery							<0.001
Yes	100	0.06%	0	0.00%	100	7.70%
No/unknown	169205	99.94%	168007	100.00%	1198	92.30%
Radiotherapy							<0.001
Yes	25351	14.97%	24993	14.88%	358	27.58%
No/unknown	143954	85.03%	143014	85.12%	940	72.42%
Chemotherapy							<0.001
Yes	59540	35.17%	58610	34.89%	930	71.65%
No/unknown	109765	64.83%	109397	65.11%	368	28.35%
Tumor size							<0.001
≤5 cm	101949	60.22%	101357	60.33%	592	45.61%
5-10 cm	41599	24.57%	41177	24.51%	422	32.51%
>10 cm	4149	2.45%	4092	2.44%	57	4.39%
NOS	21608	12.76%	21381	12.73%	227	17.49%
CEA							<0.001
Normal	59541	35.17%	59262	35.27%	279	21.49%
Elevated	35452	20.94%	34835	20.73%	617	47.53%
NOS	74312	43.89%	73910	43.99%	402	30.97%
TD							<0.001
Negative	133508	78.86%	132910	79.11%	598	46.07%
Positive	13672	8.08%	13448	8.00%	224	17.26%
NOS	22125	13.07%	21649	12.89%	476	36.67%
PNI							<0.001
Negative	132991	78.55%	132292	78.74%	699	53.85%
Positive	13079	7.73%	12863	7.66%	216	16.64%
NOS	23235	13.72%	22852	13.60%	383	29.51%
Median survival (months)	30 (13-53)		30 (13-53)		18 (8-33)		<0.001

MCC: mucinous cell carcinoma; SRCC: signet ring cell carcinoma; CEA: carcinoembryonic antigen; TD: tumor deposits; PNI: perineural invasion; NOS: not otherwise specified.